China’s National Medical Products Administration (NMPA) and National Healthcare
Security Administration (NHSA) formed a joint inspection team to screen drugs
traceability-code clues and inspect medical institutions and pharmaceuticals
wholesalers in selected cities in Inner Mongolia and Shanxi. The inspections
focus on prominent medical-insurance fund management issues and key links in
drug distribution, using drug traceability anomalies and clues of duplicate
medical-insurance claims as entry points. Agencies inspected certain hospitals
and pharmacies and said discovered violations will be strictly dealt with
according to law.